Ochre Bio is pioneering advancements in the treatment of chronic liver disease through a unique integration of computational and multi-omic technologies. The company focuses on utilizing human models to generate extensive genomic and phenotypic data, which aids in the development of RNA therapies targeting significant liver health challenges. By employing deep phenotyping techniques, Ochre maps genes to cellular and clinical data, enhancing the understanding of liver disease mechanisms. Their validation platform is recognized as one of the most advanced globally, utilizing human cell co-culture, diseased liver tissue culture, and whole liver perfusion to ensure the efficacy of their therapeutic approaches.

The company's RNA chemistry platform is designed to expedite the drug development process, allowing scientists to progress from target identification to validated lead compounds in a matter of weeks rather than years. This rapid development cycle is crucial given the rising prevalence of chronic liver disease, which is increasingly recognized as a leading global health concern. With a team composed of experts in genomics, machine learning, and drug discovery, Ochre Bio is committed to addressing the unmet medical needs of patients suffering from liver diseases, ultimately aiming to transform the landscape of liver therapy.

United Kingdom

Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. To learn more, please visit www.ochre-bio.com.

Ochre Bio

Company Details